Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 74702-93-5 | MDL No. : | MFCD11109722 |
Formula : | C9H12BrN | Boiling Point : | 245.7±15.0°C at 760 mmHg |
Linear Structure Formula : | - | InChI Key : | - |
M.W : | 214.10 g/mol | Pubchem ID : | - |
Synonyms : |
|
Num. heavy atoms : | 11 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.33 |
Num. rotatable bonds : | 1 |
Num. H-bond acceptors : | 1.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 51.31 |
TPSA : | 26.02 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -5.84 cm/s |
Log Po/w (iLOGP) : | 2.43 |
Log Po/w (XLOGP3) : | 2.49 |
Log Po/w (WLOGP) : | 2.53 |
Log Po/w (MLOGP) : | 2.91 |
Log Po/w (SILICOS-IT) : | 2.45 |
Consensus Log Po/w : | 2.56 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -3.07 |
Solubility : | 0.181 mg/ml ; 0.000844 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.68 |
Solubility : | 0.446 mg/ml ; 0.00208 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -3.72 |
Solubility : | 0.0408 mg/ml ; 0.000191 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.38 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
![]() |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With hydrogenchloride In diethyl ether | 76.4 Step 4; Preparation of 2- (3-bromophenyl)-2-propylamine hydrochloride; To 2- (3-bromophenyl)-2-propylamine 29 in ether is added ethereal HC1. Solvent removal affords a tan solid, which is dissolved in a small volume of ethanol and diluted with ethyl acetate. The tan crystals which form are filtered to afford 2- (3- bromophenyl) -2-propylamine hydrochloride |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With N-ethyl-N,N-diisopropylamine; In dichloromethane; at 20℃; for 48h; | To an ice-cooled solution of l,l-dimethyl-3-bromobenzyl amine(3.82 g, 17.8 mmol) from Step A above in dichloromethane (100 mL) was added diisopropylethylamine (3.45 g, 26.7 mmol) and 2-bromo-3,4-dchloroacetophenone (2.44 g, 8.92 mmol). The reaction mixture was stirred at room temperature for 2 days. The mixture was diluted with dichloromethane (SO mL), and washed with water and brine, dried over sodium sulfate, and concentrated under reduced pressure. The crude product was purified by flash column chromatography (10 to 30% ethyl acetate/hexanes) to give 2-(2-(3-bromophenyl)propan-2-ylamino)-l-(3,4-dichlorophenyl)ethanone (1.37 g, 38% over 2 steps): 1H NMR (CDCl3, 500 MHz) delta 7.92 (d, / = 2.0 Hz, 2H), 7.67 (dd, J = 8.4, 2.0 Hz, IH), 7.58 (t, /= 1.8 Hz, IH), 7.51 (d, /= 8.4Hz, IH), 7.377.35 (m, 2H), 7.20 (t, J = 7.9 Hz, IH), 3.83 (s, 2H), 1.51 (s, 6H). |